FrançaisModerna vs Pfizer: which stock to buy?
Head to head
| Metric | Moderna | Pfizer | Edge |
|---|---|---|---|
| Price | $143 | $28.02 | |
| Median target (12m) | $77.00 (-46%) | $28.00 (-0%) | |
| Analyst reliability (1y) | 35% | 19% | 🟢 MRNA |
| Avg gain / call (1y) | +10% | -2% | |
| P/E | — | 37.4 | 🔵 PFE |
| $1000 invested (8y ago) | $3,765 | $699 | 🟢 MRNA |
Performance by year
| Year | MRNA | PFE | Winner |
|---|---|---|---|
| 2026 | +127% | -13% | 🟢 MRNA |
| 2025 | -27% | +5% | 🔵 PFE |
| 2024 | -58% | -0% | 🔵 PFE |
| 2023 | -45% | -35% | 🔵 PFE |
| 2022 | -29% | -14% | 🔵 PFE |
| 2021 | +143% | +40% | 🟢 MRNA |
| 2020 | +453% | +6% | 🟢 MRNA |
| 2019 | +11% | -23% | 🟢 MRNA |
Frequently asked questions
Moderna or Pfizer: which to buy?
Over ~8 years, Moderna returned $3,765 on $1000 vs $699 for Pfizer, and Moderna has better analyst reliability. Not advice: also check valuation (P/E) and your horizon.
Moderna vs Pfizer: which performed best?
Over ~8 years, Moderna wins ($3,765 vs $699 on $1000 invested, price return excluding dividends).
Moderna vs Pfizer: which is cheaper?
On P/E, Pfizer is cheaper (— vs 37.4). A lower P/E isn't always a better deal (growth matters).
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Past price performance (excluding dividends). Data: Yahoo Finance.